Is PACB or PRE more undervalued in 2026?

CirclFi compares Pacific Biosciences of Californ (PACB) and Prenetics Global Limited (PRE) using 13 institutional-grade valuation models. PACB has a Quality of Company score of 5.7/10 while PRE scores 4.6/10.

Which is a better buy — PACB or PRE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PACB and PRE valuations compare?

PACB at $1.49 and PRE at $21.10 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PACB vs PRE Valuation Comparison 2026 — Intrinsic Value Analysis

PACB

Laboratory Analytical Instruments

Pacific Biosciences of Californ

Quality

5.7

out of 10

Value Trap

WARN

Price

$1.49

Last close

Models

11/13

Active

PRE

Laboratory Analytical Instruments

Prenetics Global Limited

Quality

4.6

out of 10

Value Trap

LOW

Price

$21.10

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	PACB Fair Value	PACB Upside	PRE Fair Value	PRE Upside
Bayesian DCF	Intrinsic	$2.54	+48.4%	$8.94	-57.6%
Earnings Power Value	Intrinsic	$1.49	-6.6%	$7.16	-58.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PACB vs PRE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PACB vs PRE — Which Stock Is More Undervalued?

PACB scores higher with a 5.7/10 quality rating vs PRE's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pacific Biosciences of Californ (PACB) and Prenetics Global Limited (PRE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PACB currently trades at $1.49 with a QOC of 5.7/10, while PRE trades at $21.10 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).